References
- Lane CR, Carville KS, Pierse N, et al. Seasonal influenza vaccine effectiveness estimates: development of a parsimonious case test negative model using a causal approach. Vaccine. 2016;34(8):1070–1076.
- Koutsakos M, Nguyen TH, Barclay WS, et al. Knowns and unknowns of influenza B viruses. Future Microbiol. 2016;11(1):119–135.
- van de Sandt CE, Bodewes R, Rimmelzwaan GF, et al. Influenza B viruses: not to be discounted. Future Microbiol. 2015;10(9):1447–1465.
- Shu Y, Guo Y. Review of the molecular biology of influenza B virus. Foreihg Med Sci. 1996;3(1):3–8.
- Suryadevara M, Domachowske JB. Quadrivalent influenza vaccine in the United States. Hum Vaccin Immunother. 2014;10(3):596–599.
- Mosterín Höpping A, Fonville JM, Russell CA, et al. Influenza B vaccine lineage selection–an optimized trivalent vaccine. Vaccine. 2016;34(13):1617–1622.
- Robertson JS, Naeve CW, Webster RG, et al. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology. 1985;1(143):166–174.
- Yang F, Liao G. Review of detection methods of influenza B virus. Int J Lab Med. 2013;34(10):1258–1260.
- Yu W, Yang F, Yang J, et al. Construction high-yield candidate influenza vaccine viruses in Vero cells by reassortment. J Med Virol. 2016;88(11):1914–1921.
- Bandell AR, Simões EA. Live attenuated influenza vaccine tetravalent: a clinical review. Expert Rev Vaccines. 2015;14(7):963–973.
- Chung JR, Flannery B, Thompson MG, et al. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics. 2016;137(2):e20153279.
- Chen Z, Aspelund A, Kemble G, et al. Molecular studies of temperature-sensitive replication of the cold-adapted B/Ann Arbor/1/66, the master donor virus for live attenuated influenza FluMist vaccines. Virology. 2008;380(2):354–362.
- Liu Z, Li WD, Sun MB, et al. Screening of a high growth influenza B virus strain in Vero cells. Virol Sin. 2010;25(1):65–70.
- Reed LJ, Muench H. A simple method of estimating fifty per cent end points. Am J Hyg. 1938;27:493–497.
- Zhou F, Zhou J, Ma L, et al. High-yield production of a stable Vero cell-based vaccine candidate against the highly pathogenic avianinfluenza virus H5N1. Biochem Biophys Res Commun. 2012;421(4):850–854.
- Zhou J, Yang F, Yang J, et al. Reassortment of high-yield influenza viruses in Vero cells and safety assessment as candidate vaccines trains. Hum Vaccin Immunother. 2016;20:1–6.
- Balannik V, Wang J, Ohigashi Y, et al. Design and pharmacological characterization of inhibitors of amantadine-resistant mutants of the M2 ionchannel of influenza A virus. Biochemistry. 2009;48(50):11872–11882.
- Meng Y, Liu B, Lei N, et al. Alpha-momorcharin possessing high immunogenicity, immunotoxicity and hepatotoxicity in SD rats. J Ethnopharmacol. 2012;139(2):590–598.
- Basketter DA, Scholes EW. Comparison of the local lymph node assay with the guinea-pig maximization test for the detection of arange of contact allergens. Food Chem Toxicol. 1992;30(1):65–69.
- Hong BO, Li-Bo DONG, Ye ZHANG, et al. Establishment of micro-plaque reduction assay to detect human serum neutralization antibody level against avian influenza A(H7N9) virus. Dis Surveill. 2016;2:126–129.
- Seo SU, Byun YH, Lee EY, et al. Development and characterization of a live attenuated influenza B virus vaccine candidate. Vaccine. 2008;26(7):874–881.
- Kittel C, Wressnigg N, Shurygina AP, et al. A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice. Arch Virol. 2015;160(10):2525–2534.
- Johnson A, Chen LM, Winne E, et al. Identification of Influenza A/PR/8/34 donor viruses imparting high hemagglutinin yields to candidatevaccine viruses in eggs. PLoS One. 2015;10(6):e012898.
- Wareing MD, Marsh GA, Tannock GA. Preparation and characterisation of attenuated cold-adapted influenza A reassortants derived from the A/Leningrad/134/17/57 donor strain. Vaccine. 2002;20(16):2082–2090.
- Alexandrova GI, Maassab HF, Kendal AP, et al. Laboratory properties of cold-adapted influenza B live vaccine strains developed in the US and USSR, and their B/Ann Arbor/1/86 cold-adapted reassortant vaccine candidates. Vaccine. 1990;8(1):61–64.
- Maassab HF, Bryant ML. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol. 1999;9(4):237–244.